Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Monday, February 8, 2010

Yale researchers ID disease-treating proteins

By Mass High Tech staff

Yale scientists have developed color-coded proteins that researchers can use to identify proteins to treat diseases, according to the school.

Anthony van den Pol, a professor of neurosurgery, and John Davis, a molecular biologist, have figured out how to use a mutation-prone virus engineered to express fluorescent proteins to find proteins researchers could use against diseases. The virus generates mutated genes that code for these proteins and expresses them within cells so scientists can study their function. The procedure could streamline research to identify and study novel mutant proteins, according to the researchers.

The researchers made the discovery while studying viruses as a means of attacking brain cancers.

The discovery is detailed in the February issue of the Journal of Virology.

 

Add your comment, and share it via Facebook, LinkedIn, Yahoo and more. Edit your Disqus profile settings.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

On the MHT blog now

ITA Software buyout reported to stir up concern

The proposed $700 million acquisition of Boston-based ITA Software Inc.  by Google Inc. has apparently raised the concern level of some other tech giants. Seattle TechFlash has pointed to a Wall Street Journal article reporting that Microsoft Corp. and Expedia Inc. have cried foul and noting the “unfair advantage” Google could gain from acquiring the flight-information software maker. Conc...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio